BridgeBio’s Big Growth Turnaround | Business and Finance News

episode

Business News Today | 2 Min News | The Daily News Now! not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

More from Business News Today | 2 Min News | The Daily News Now!

Japanese Capsule Hotels: Budget Solution for London Hybrid Workers 1 min · 20 Dec 2025

Russia's War Economy: Sustainable or Unsustainable? 2 min · 20 Dec 2025

All episodes from Business News Today | 2 Min News | The Daily News Now! →

Report any issue

Source

Recorded19 Aug 2026

Publisherfeeds.acast.com ↗

Handlerec:20064583

Show notes

BridgeBio Pharma is on fire—its drug Attruby is exploding in growth, up 23%, with new data hinting it may protect kidneys for ATTR-CM patients. Three late-stage drugs hit the FDA, one with a November 2026 decision date, and they just landed $1 billion to fuel launches. CEO calls this “Launch 2.0”—expect big commercial wins in 6-9 months. Beyond Attruby, they’re racing toward Phase 3 results for hypoparathyroidism and eyeing a new TTR antibody trial within 18 months. This isn’t just momentum—it’s a full-scale growth engine primed for major returns. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/fb58b94fd81682de

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.